"Antimyeloangiogenic" Therapy for Cancer by Inhibiting PIGF

被引：56

作者：

Loges, Sonja ^{[1
]}

Schmidt, Thomas ^{[1
]}

Carmeliet, Peter ^{[1
]}

机构：

[1] Katholieke Univ Leuven, VIB, Vesalius Res Ctr, B-3000 Louvain, Belgium

来源：

CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 11期

关键词：

ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; FACTOR RECEPTOR-1; PROGNOSTIC VALUE; TUMOR VASCULATURE; VEGF RECEPTORS; UP-REGULATION; IN-VITRO; EXPRESSION; FLT-1;

D O I：

10.1158/1078-0432.CCR-08-2276

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibition of tumor angiogenesis emerged as valuable strategy to treat cancer and has revolutionized the face of clinical oncology by prolonging the life of numerous cancer patients. However, the duration of this response is rather short and tumors rapidly evade treatment, leaving antiangiogenic treatment thus far unable to cure cancer. Hence, novel targets are needed to diversify antiangiogenic treatments and to overcome resistance. Recent data support the concept that tumor infiltration by bone marrow-derived myeloid cells confers resistance to current antiangiogenic drugs targeting primarily vascular endothelial growth factor (VEGF). In this review, we will summarize (pre)clinical data on the role of PIGF and its receptor VEGFR-1 in promoting angiogenesis and inflammation, and the "antimyeloangiogenic" activity of an antibody against PIGF (alpha PIGF), which may help to overcome resistance against VEGF (R) Is. Because of these promising results, a humanized alpha PIGF antibody (TB403) is currently evaluated in different phase I clinical trials in cancer patients.

引用

页码：3648 / 3653

页数：6

共 78 条

[1] Phase II study of sorafenib in patients with advanced hepatocellular carcinoma [J].

Abou-Alfa, Ghassan K. ;

Schwartz, Lawrence ;

Ricci, Sergio ;

Amadori, Dino ;

Santoro, Armando ;

Figer, Arie ;

De Greve, Jacques ;

Douillard, Jean-Yves ;

Lathia, Chetan ;

Schwartz, Brian ;

Taylor, Ian ;

Moscovici, Marius ;

Saltz, Leonard B. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4293-4300

[2]

Adini A, 2002, CANCER RES, V62, P2749

[3]

Amaoka N, 2006, ONCOL REP, V16, P3

[4]

André T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.0.CO

[5]

2-E

[6] Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J].

Azad, Nilofer S. ;

Posadas, Edwin M. ;

Kwitkowski, Virginia E. ;

Steinberg, Seth M. ;

Jain, Lokesh ;

Annunziata, Christina M. ;

Minasian, Lori ;

Sarosy, Gisele ;

Kotz, Herbert L. ;

Premkumar, Ahalya ;

Cao, Liang ;

McNally, Deborah ;

Chow, Catherine ;

Chen, Helen X. ;

Wright, John J. ;

Kohn, Elise C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3709-3714

[7] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[8] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[9] Hypoxia and cancer [J].

Brahimi-Horn, M. Christiane ;

Chiche, Johanna ;

Pouyssegur, Jacques .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2007, 85 (12) :1301-1307

[10] Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].

Carmeliet, P ;

Ferreira, V ;

Breier, G ;

Pollefeyt, S ;

Kieckens, L ;

Gertsenstein, M ;

Fahrig, M ;

Vandenhoeck, A ;

Harpal, K ;

Eberhardt, C ;

Declercq, C ;

Pawling, J ;

Moons, L ;

Collen, D ;

Risau, W ;

Nagy, A .

NATURE, 1996, 380 (6573) :435-439

← 1 2 3 4 5 6 7 8 →